For the MedTech industry there was a mixed bag of results, innovation and regulatory changes. Venture capital has not returned to pre-2008 levels in most medical technology sectors, the medical device tax in the United States was widely debated by industry, US Congress and the news media. I found the following reports helpful in understanding this mixed bag.
AdvaMed summary of cuts and taxes impacting medical industry (Aug 2013)
PWC – Q3 2013 report illustrates the funding landscape, top metropolitan areas for investing in biotech/medtech.
Author: John S. Bolinder | Google+